These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 23673402)

  • 1. Levosimendan for the treatment of subarachnoid hemorrhage-related cardiogenic shock.
    Taccone FS; Brasseur A; Vincent JL; De Backer D
    Intensive Care Med; 2013 Aug; 39(8):1497-8. PubMed ID: 23673402
    [No Abstract]   [Full Text] [Related]  

  • 2. Use of levosimendan for cardiogenic shock in a patient with the apical ballooning syndrome.
    De Santis V; Vitale D; Tritapepe L; Greco C; Pietropaoli P
    Ann Intern Med; 2008 Sep; 149(5):365-7. PubMed ID: 18765717
    [No Abstract]   [Full Text] [Related]  

  • 3. Use of levosimendan for treatment of cardiogenic shock associated with electrical storm.
    Grazi M; Lauri G; Carbucicchio C; Marenzi G
    Ann Intern Med; 2009 May; 150(10):738-40. PubMed ID: 19451590
    [No Abstract]   [Full Text] [Related]  

  • 4. Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome.
    Schumann J; Henrich EC; Strobl H; Prondzinsky R; Weiche S; Thiele H; Werdan K; Frantz S; Unverzagt S
    Cochrane Database Syst Rev; 2018 Jan; 1(1):CD009669. PubMed ID: 29376560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Levosimendan is superior to enoximone in refractory cardiogenic shock complicating acute myocardial infarction.
    Fuhrmann JT; Schmeisser A; Schulze MR; Wunderlich C; Schoen SP; Rauwolf T; Weinbrenner C; Strasser RH
    Crit Care Med; 2008 Aug; 36(8):2257-66. PubMed ID: 18664782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inotropic agents and vasodilator strategies for acute myocardial infarction complicated by cardiogenic shock or low cardiac output syndrome.
    Unverzagt S; Wachsmuth L; Hirsch K; Thiele H; Buerke M; Haerting J; Werdan K; Prondzinsky R
    Cochrane Database Syst Rev; 2014 Jan; (1):CD009669. PubMed ID: 24385385
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of levosimendan in Takotsubo-related cardiogenic shock.
    Antonini M; Stazi GV; Cirasa MT; Garotto G; Frustaci A
    Acta Anaesthesiol Scand; 2010 Jan; 54(1):119-20. PubMed ID: 19961441
    [No Abstract]   [Full Text] [Related]  

  • 8. Importance of levosimendan on right ventricular function in patients with biventricular heart failure.
    Erdem A; Birhan Yilmaz M
    Crit Care Med; 2010 May; 38(5):1389-90; author reply 1390-1. PubMed ID: 20404640
    [No Abstract]   [Full Text] [Related]  

  • 9. Levosimendan is superior to enoximone in refractory cardiogenic shock complicating acute myocardial infarction.
    Beute J
    Crit Care Med; 2009 Sep; 37(9):2678; author reply 2678-9. PubMed ID: 19687655
    [No Abstract]   [Full Text] [Related]  

  • 10. [Paediatric use of levosimendan in septic shock].
    Monteverde E; Neira P; Farías J
    An Pediatr (Barc); 2008 May; 68(5):529-30. PubMed ID: 18448005
    [No Abstract]   [Full Text] [Related]  

  • 11. Myocardial depression associated with pneumococcal septic shock reversed by levosimendan.
    Ramaswamykanive H; Bihari D; Solano TR
    Anaesth Intensive Care; 2007 Jun; 35(3):409-13. PubMed ID: 17591138
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Successful use of levosimendan in a patient with cardiogenic shock complicating acute myocardial infarction].
    Mustapha F; Moufida H; Nedia B; Anis L; Iheb L; Habib H
    Tunis Med; 2005 Oct; 83(10):635-7. PubMed ID: 16370217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Levosimendan neither improves nor worsens mortality in patients with cardiogenic shock due to ST-elevation myocardial infarction.
    Omerovic E; Råmunddal T; Albertsson P; Holmberg M; Hallgren P; Boren J; Grip L; Matejka G
    Vasc Health Risk Manag; 2010 Sep; 6():657-63. PubMed ID: 20859537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Levosimendan as a treatment for acute renal failure associated with cardiogenic shock after hip fracture.
    Hinojosa FQ; Revelo M; Salazar A; Maggi G; Schiraldi R; Brogly N; Gilsanz F
    Braz J Anesthesiol; 2017; 67(1):89-91. PubMed ID: 28017176
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Levosimendan: right for the right ventricle?
    Lambermont B; Ghuysen A; Harstein G; D'Orio V
    Crit Care Med; 2007 Aug; 35(8):1995-6. PubMed ID: 17667254
    [No Abstract]   [Full Text] [Related]  

  • 16. Levosimendan in cardiogenic shock: better than enoximone!
    Buerke M; Prondzinsky R
    Crit Care Med; 2008 Aug; 36(8):2450-1. PubMed ID: 18664796
    [No Abstract]   [Full Text] [Related]  

  • 17. Levosimendan or enoximone in refractory cardiogenic shock?
    Berthelsen PG
    Crit Care Med; 2009 Mar; 37(3):1182. PubMed ID: 19237971
    [No Abstract]   [Full Text] [Related]  

  • 18. Levosimendan in cardiogenic shock: the magic drug for every patient?
    Smetana P; Geppert A
    Crit Care Med; 2007 Dec; 35(12):2862-4. PubMed ID: 18043208
    [No Abstract]   [Full Text] [Related]  

  • 19. Initial experience with levosimendan infusion for preoperative management of hypoplastic left heart syndrome.
    Di Chiara L; Ricci Z; Garisto C; Morelli S; Giorni C; Vitale V; Di Donato RM; Picardo S
    Pediatr Cardiol; 2010 Jan; 31(1):166-7. PubMed ID: 19915896
    [No Abstract]   [Full Text] [Related]  

  • 20. Concomitant levosimendan and esmolol infusion in ischaemic cardiogenic shock.
    Guarracino F; Landoni G; Baldassarri R; Nobile L; Stefani M
    Br J Anaesth; 2010 Mar; 104(3):388-9. PubMed ID: 20150349
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.